ORION PHARMA LIMITED AND ITS SUBSIDIARIES FINANCIAL STATEMENTS (UNAUDITED) AS ON 30TH SEPTEMBEER 2016 (1ST QUARTER)

ORION PHARMA LIMITED AND ITS SUBSIDIARIES

Consolidated Statement of Financial Position (Unaudited) As at 30 September, 2016

				Amount In BDT		
				30-Sep-16	30-Jun-16	
Assets						
Non-Current As	sets			18,122,249,543	18,286,613,233	
Property, Plant a	and Equipment			13,944,459,528	14,058,343,411	
Construction Wo	ork in Progress			1,653,174,677	1,591,424,708	
Investment in A	ssociates			304,784,000	319,403,000	
Other Investmen	nts			2,219,831,338	2,317,442,114	
Current Assets				9,382,504,783	8,603,292,025	
Inventories				760,402,459	681,075,164	
Trade and Other	r Receivables			7,420,636,230	6,807,087,245	
Advances, Depo	sits & Prepayments			1,032,760,862	872,933,890	
Fixed Deposit w	ith Banks			6,862,748	6,757,702	
Cash and Cash l	Equivalents			161,842,485	235,438,024	
Total Assets				27,504,754,325	26,889,905,259	
Equity and Liab	oilities					
Shareholders' E	quity			16,634,618,796	16,377,819,562	
Share Capital				2,340,000,000	2,340,000,000	
Share Premium				8,016,892,026	8,016,892,026	
Reserves				2,059,089,935	2,083,239,547	
Retained Earnin	igs			4,218,636,835	3,937,687,989	
Non - Controllia	ng Interest			882,051,164	838,306,456	
Total Equity				17,516,669,959	17,216,126,019	
Non-Current Li	abilities			5,193,265,497	5,663,366,765	
Redeemable Pre	eference Share			500,000,000	500,000,000	
Long Term Loan				4,451,780,046	4,925,434,529	
Provision for De	ecommissioning of Assets			143,405,563	143,405,563	
Employee Bene				21,517,493	19,989,957	
Deferred Tax Li	ability			76,562,397	74,536,715	
Current Liabili	ties			4,794,818,868	4,010,412,475	
Short Term Loa	n			813,129,864	833,781,938	
Trade and Othe				2,665,276,351	834,243,833	
Accrued Expen	ses			1,316,412,653	2,342,386,70	
Total equity &	Liabilities			27,504,754,325	26,889,905,259	
Number of Sha	ares used to compute NAV	7,		234,000,000	234,000,00	
Net Asset Valu	e (NAV) Including Reval	uation Surplu	15	71.09	69.9	
	e (NAV) Excluding Reval			62.51	61.3	
Sd/-	Sd/-	Sd/-		Sd/-	Sd/-	
Chairman	Managing Director	Director	Chief Financ	ial Officer	Company Secretar	

Statement of Financial Position (Unaudited) As at 30 September, 2016

Amount In BDT

Property, Plant and Equipment Construction Work in Progress Investment in Subsidiaries Investment in Associates Other Investments Current Assets Inventories Trade and Other Receivables Advances, Deposits & Prepayments Fixed Deposit with Banks Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	9,907,430,300 4,712,640,285 1,653,174,677 1,017,000,000 304,784,000 2,219,831,338 5,824,778,753 280,120,114 4,632,222,194 860,478,797 6,862,748 45,094,899	9,910,680,477 4,665,410,654 1,591,424,709 1,017,000,000 319,403,000 2,317,442,114 5,800,753,696 299,950,084 4,774,886,093 685,884,662 6,757,702 33,275,154
Property, Plant and Equipment Construction Work in Progress Investment in Subsidiaries Investment in Associates Other Investments Current Assets Inventories Trade and Other Receivables Advances, Deposits & Prepayments Fixed Deposit with Banks Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	4,712,640,285 1,653,174,677 1,017,000,000 304,784,000 2,219,831,338 5,824,778,753 280,120,114 4,632,222,194 860,478,797 6,862,748 45,094,899	4,665,410,654 1,591,424,709 1,017,000,000 319,403,000 2,317,442,114 5,800,753,696 299,950,084 4,774,886,093 685,884,662 6,757,702
Construction Work in Progress Investment in Subsidiaries Investment in Associates Other Investments Current Assets Inventories Trade and Other Receivables Advances, Deposits & Prepayments Fixed Deposit with Banks Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	1,653,174,677 1,017,000,000 304,784,000 2,219,831,338 5,824,778,753 280,120,114 4,632,222,194 860,478,797 6,862,748 45,094,899	1,591,424,709 1,017,000,000 319,403,000 2,317,442,114 5,800,753,696 299,950,084 4,774,886,093 685,884,662 6,757,702
Investment in Subsidiaries Investment in Associates Other Investments Current Assets Inventories Trade and Other Receivables Advances, Deposits & Prepayments Fixed Deposit with Banks Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	1,017,000,000 304,784,000 2,219,831,338 5,824,778,753 280,120,114 4,632,222,194 860,478,797 6,862,748 45,094,899	1,017,000,000 319,403,000 2,317,442,114 5,800,753,696 299,950,084 4,774,886,093 685,884,662 6,757,702
Investment in Associates Other Investments Current Assets Inventories Trade and Other Receivables Advances, Deposits & Prepayments Fixed Deposit with Banks Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	304,784,000 2,219,831,338 5,824,778,753 280,120,114 4,632,222,194 860,478,797 6,862,748 45,094,899	319,403,000 2,317,442,114 5,800,753,696 299,950,084 4,774,886,093 685,884,662 6,757,702
Other Investments Current Assets Inventories Trade and Other Receivables Advances, Deposits & Prepayments Fixed Deposit with Banks Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	2,219,831,338 5,824,778,753 280,120,114 4,632,222,194 860,478,797 6,862,748 45,094,899	2,317,442,114 5,800,753,696 299,950,084 4,774,886,093 685,884,662 6,757,702
Current Assets Inventories Trade and Other Receivables Advances, Deposits & Prepayments Fixed Deposit with Banks Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	5,824,778,753 280,120,114 4,632,222,194 860,478,797 6,862,748 45,094,899	5,800,753,696 299,950,084 4,774,886,093 685,884,662 6,757,702
Inventories Trade and Other Receivables Advances, Deposits & Prepayments Fixed Deposit with Banks Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	280,120,114 4,632,222,194 860,478,797 6,862,748 45,094,899	299,950,084 4,774,886,093 685,884,662 6,757,702
Inventories Trade and Other Receivables Advances, Deposits & Prepayments Fixed Deposit with Banks Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	280,120,114 4,632,222,194 860,478,797 6,862,748 45,094,899	299,950,084 4,774,886,093 685,884,662 6,757,702
Trade and Other Receivables Advances, Deposits & Prepayments Fixed Deposit with Banks Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	4,632,222,194 860,478,797 6,862,748 45,094,899	4,774,886,093 685,884,662 6,757,702
Advances, Deposits & Prepayments Fixed Deposit with Banks Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	860,478,797 6,862,748 45,094,899	685,884,662 6,757,702
Fixed Deposit with Banks Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	6,862,748 45,094,899	6,757,702
Cash and Cash Equivalents Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	45,094,899	
Total Assets Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan		0012101101
Equity and Liabilities Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan		
Shareholders' Equity Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	15,732,209,052	15,711,434,172
Share Capital Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan		40 404 (FB 8 (0
Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	13,199,814,575	13,191,673,369
Share Premium Retained Earnings Reserves Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	2,340,000,000	2,340,000,000
Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	8,016,892,026	8,016,892,026
Non-current Liabilities Employee Benefit Provision Deferred Tax Liability Long term loan	1,227,439,845	1,199,115,795
Employee Benefit Provision Deferred Tax Liability Long term loan	1,615,482,705	1,635,665,548
Employee Benefit Provision Deferred Tax Liability Long term loan	811,189,308	819,728,530
Deferred Tax Liability Long term loan	21,517,493	19,989,957
Long term loan	76,562,397	74,536,715
	713,109,417	725,201,858
Current Liabilities	1,721,205,169	1,700,032,273
Short Term Loans	813,129,864	833,781,938
Trade & Other Payables	416,222,829	431,495,332
Accrued Expenses	491,852,476	434,755,003
Total equity & Liabilities	15,732,209,052	15,711,434,172
Number of Shares used to compute NAV	234,000,000	234,000,000
Net Asset Value (NAV) Including Revaluation Surplus	56.41	56.37
	50.27	50.22
Net Asset Value (NAV) Excluding Revaluation Surplus		
Sd/- Sd/- Sd/- Sd/- Chairman Managing Director Director Chief Financial		Sd/- Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited)
For the 1st quarter ended 30 September, 2016

	Amount	In BDT
	1 July to 30	1 July to 30
	September 2016	September 2015
Revenue from Net Sales	2,619,320,901	2,763,992,348
Cost of Goods Sold	(303,914,812)	(168,778,992)
Cost of Power Generation	(1,642,974,816)	(1,773,913,304)
Gross Profit	672,431,273	821,300,052
Operating Expenses	(195,677,239)	(411,035,683)
General & Administrative Expenses	(70,568,745)	(286,618,671)
Selling & Distribution Expenses	(125,108,493)	(124,417,012)
Profit from Operation	476,754,035	410,264,368
Financial Expenses	(161,519,153)	(217,813,981)
Interest & Other Income	9,246,108	17,187,377
Net Profit from Operation	324,480,990	209,637,764
Workers Profit Participation Fund	(1,527,536)	(1,306,071)
Net Profit before Tax	322,953,454	208,331,693
Income Tax	(7,863,407)	(5,935,869)
Current Tax Expenses/Income	(7,627,773)	(4,645,906)
Deferred Tax Expenses	(235,635)	(1,289,963)
Net Profit after Tax	315,090,047	202,395,824
Share of Profit from Associate	1,594,800	310,100
Net Profit	316,684,847	202,705,924
Less: Non Controlling Interest (share of operating profit)	(43,744,711)	(32,632,393)
Net Profit after Tax before Other Comprehensive Income	272,940,136	170,073,531
Add: Other Comprehensive Income	(25,204,671)	102,808,739
Fair Value Gain of Marketable Securities	(8,990,871)	39,769,839
Share of Other Comprehensive Income	1,672,343	9,458,804
Fair Value Gain on Investment in Associates	(17,886,143)	53,580,096
Total Comprehensive Income Attributable to Ordinary Share Holder	247,735,465	272,882,270
Number of Shares used to compute EPS	234,000,000	234,000,000
Basic Earning Per Share (EPS)	1.17	0.73

Sd/-	Sd/-	Sd/-	Sd/-	Sd/-
Chairman	Managing Director	Director	Chief Financial Officer	Company Secreta

Statement of Profit or Loss and Other Comprehensive Income (Unaudited) For the 1st quarter ended 30 September, 2016

	Amount In BDT	
	1 July to 30 September 2016	1 July to 30 September 2015
Revenue from Net Sales	548,384,720	332,358,766
Cost of Goods Sold	(303,914,812)	(168,778,992)
Gross Profit	244,469,908	163,579,774
Operating Expenses	(185,366,410)	(135,787,001)
General & Administrative Expenses	(60,257,916)	(11,369,989)
Selling & Distribution Expenses	(125,108,493)	(124,417,012)
Profit from Operation	59,103,499	27,792,773
Financial Expenses	(36,271,348)	(17,552,659)
Interest & Other Income	9,246,108	17,187,377
Net Profit from Operation	32,078,259	27,427,491
Workers Profit Participation Fund	(1,527,536)	(1,306,071)
Net Profit before Tax	30,550,723	26,121,420
Income Tax	(7,863,407)	(5,935,869)
Current Tax Expenses	(7,627,773)	(4,645,906)
Deferred Tax Expenses/Income	(235,635)	(1,289,963)
Net Profit after Tax	22,687,316	20,185,551
Share of Profit from Associates	1,594,800	310,100
Net Profit after Tax before Other Comprehensive Income	24,282,116	20,495,651
Add: Other Comprehensive Income	(22,943,353)	102,808,739
Fair Value Gain of Marketable Securities	(8,990,871)	39,769,839
Fair Value Gain on Investment in Associate	(17,886,143)	53,580,096
Deferred tax income/expense on revaluation Surplus during the	2,261,318	
Share of Other Comprehensive Income	1,672,343	9,458,804
Total Comprehensive Income attribute to Ordinary Share Holders	1,338,763	123,304,390
Number of Shares used to compute EPS	234,000,000	234,000,000
Basic Earning Per Share (EPS)	0.10	0.09

Sd/- Sd/- Sd/- Sd/- Sd/- Sd/- Sd/- Chairman Managing Director Director Chief Financial Officer Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES

Consolidated Statement of Changes in Equity (Unaudited) For the 1st quarter ended 30 September, 2016

Amount in BDT

Particulars	Ordinary Share Capital	Share Premium	Retained Earnings	Reserves	Total
Balance at 01 July 2015	2,340,000,000	8,016,892,026	3,582,152,413	2,045,297,378	15,984,341,817
Net Profit after Tax	-	-	170,073,531	-	170,073,531
Cash Dividend for the year 2014	-	-	-	-	-
Fair Value Gain on Investment in Associates	-	-	_	53,580,096	53,580,096
Fair Value gain on Marketable Securities	-	-	-1	39,769,839	39,769,839
Share of Other Comprehensive Income	•	-	,-,	9,458,804	9,458,804
Depreciation on Revaluation Surplus		-	9,236,614	(9,236,614)	-
Adjustment for loss of control from Subsidiaries	-	-	-		-
Balance at 30 September 2015	2,340,000,000	8,016,892,026	3,761,462,558	2,138,869,502	16,257,224,086
Balance at 01 July 2016	2,340,000,000	8,016,892,026	3,937,687,989	2,083,239,547	16,377,819,562
Net Profit after Tax	-	-	272,940,136		272,940,136
Fair Value Gain on Investment in Associates	-	=	-	(17,886,143)	
Fair Value gain on Marketable Securities	-	-	-	(8,990,871)	
Adjustment for sale of Mkt. Securities	-	-	-	6,802,444	6,802,444
Share of Other Comprehensive Income	-	-	-	1,672,343	1,672,343
Depreciation on Revaluation Surplus	-	-	8,008,710	(8,008,710)	-
Adjustment of deffered tax on revaluation surplus	-	=	=	2,261,325	2,261,325
Balance at 30 September 2016	2,340,000,000	8,016,892,026	4,218,636,835	2,059,089,936	16,634,618,796

Sd/-Sd/-Sd/-Sd/-Sd/-ChairmanManaging DirectorDirectorChief Financial OfficerCompany Secretary

Statement of Changes in Equity (Unaudited)

For the 1st quarter ended 30 September, 2016

Amount in BDT

Particulars	Ordinary Share Capital	Share Premium	Retained Earnings	Reserves	Total
Balance at 01 July 2015	2,340,000,000	8,016,892,026	1,093,733,400	1,581,725,294	13,032,350,720
Net Profit after tax	=	-	20,495,651	-	20,495,651
Fair Value gain on Investment in Associates	-	-	-	53,580,096	53,580,096
Share of other comprehensive Income	- (H	-	9,458,804	9,458,804
Adjustment for sale of Mkt. Securities	-	-	-	-	-
Fair Value gain on Marketable Securities	-	i.e.	-	39,769,839	39,769,839
Adjustment of deferred tax on revaluation Surplus	-	-	-	· ·	-
Adjustment for Dep on Revaluation Surplus	-	-	4,877,026	(4,877,026)	_
Balance at 30 September 2015	2,340,000,000	8,016,892,026	1,119,106,077	1,679,657,007	13,155,655,110
Balance at 01 July 2016	2,340,000,000	8,016,892,026	1,199,115,794	1,635,665,548	13,191,673,369
Net Profit after Tax	-	-	24,282,116	-	24,282,116
Fair Value Gain on Investment in Associates	-	~	-	(17,886,143)	(17,886,143)
Fair Value (Loss)/Gain on Marketable Securities	-	-	-	(8,990,871)	(8,990,871)
Adjustment for sale of Mkt. Securities		-	-	6,802,444	6,802,444
Share of Other Comprehensive Income		-	-	1,672,343	1,672,343
Adjustment of deferred tax on revaluation Surplus	-	=	-	2,261,318	2,261,318
Depreciation on Revaluation Surplus	-	-	4,041,935	(4,041,935)	s - 1
Balance at 30 September 2016	2,340,000,000	8,016,892,026	1,227,439,845	1,615,482,705	13,199,814,576

Sd/-Chairman Sd/-

Managing Director

Sd/-**Director** Sd/-Chief Financial Officer Sd/-Company Secretary

AND ITS SUBSIDIARIES

Consolidated Statement of Cash Flows (Unaudited) For the 1st quarter ended 30 September, 2016

A. Cash Flows from Operating Activities: Cash Received from Customers Cash paid to Suppliers Cash Payment for Operating Expenses Cash Payment for Operating Expenses Cash Generated from Operation Cash Payment for Income Tax Net Cash Generated/(Used) from Operating Activities B. Cash Flows from Investing Activities: Cash Flows from Investing Activities: Acquisition of Property, Plant & Equipment Capital Work in Progress Investment in Subsidiaries, Associate & Securities Investment in FDR Interest, Dividend & Other Income Net Cash Received/(Used) in Investing Activities C. Cash Flows from Financing Activities Long Term Loan Received / (Repaid) Short Term Loan Received / (Repaid) Pinancial expenses paid Dividend paid Net Cash Received/(Used) in Financing Activities C. Cash Flows from Financing Activities Long Term Loan Received / (Repaid) Pinancial expenses paid Dividend paid Net Cash Received/(Used) in Financing Activities Net		Amount In BDT		
A. Cash Flows from Operating Activities: Cash Received from Customers Cash paid to Suppliers Cash Payment for Operating Expenses Cash Payment for Income Tax Cash Payment for Income Tax Cash Generated/Used) from Operating Activities B. Cash Flows from Investing Activities: Acquisition of Property, Plant & Equipment Capital Work in Progress Investment in Subsidiaries, Associate & Securities Investment in FDR Interest, Dividend & Other Income Net Cash Received/(Used) in Investing Activities C. Cash Flows from Financing Activities: Long Term Loan Received / (Repaid) Short Term Loan Received / (Repaid) Short Term Loan Received / (Repaid) Short Term Loan Received / (Repaid) Net Cash Received/(Used) in Financing Activities Net Cash Received/(Used) in Financing Activities Net Cash Received/(Used) in Financing Activities C. Cash Flows from Financing Activities: Long Term Loan Received / (Repaid) Short Term Loan Received / (Repaid) Net Cash Received/(Used) in Financing Activities Net Increase / (Decrease) in Cash & Cash Equivalents (A-B+C) Cash & Cash Equivalents at the beginning of the year Cash & Cash Equivalents at the end of the year 161,842,485 17,94,381,227 17,94,381,274 17,94,381,274 17,94,381,274 17,94,381,274 17,94,381,274 17,64,798 17,644,798 275,085,559 (6667,771) (6667,771) (6667,771) (71,507,595) (6667,771) (71,507,595) (66667,771) (71,507,595) (66667,771) (71,507,595) (66667,771) (6667,771) (71,507,595) (66667,771) (71,507,595) (66667,771) (71,507,595) (66667,771) (71,507,595) (6667,771) (71,507,595) (66667,771) (71,507,595) (66667,771) (71,507,595) (66667,771) (71,507,595) (66667,771) (71,507,595) (66667,771) (71,507,595) (71,507,595) (71,507,595) (72,910,589) (73,95,50,60) (73,95,50,70) (73,95,50,70) (73,95,50,70) (73,95,50,70) (73,95,50,70) (73,95,50,70) (73,95,50,70) (73,95,50,		1 July to 30	1 July to 30	
Cash Received from Customers 1,874,733,822 1,794,381,274 Cash paid to Suppliers (1,258,476,753) (1,691,960,513) Cash Payment for Operating Expenses (298,789,460) 172,664,798 Cash Generated from Operation 317,467,609 275,085,559 Cash Payment for Income Tax (5,441,739) (23,078,358) Net Cash Generated/(Used) from Operating Activities 312,025,870 252,007,201 B. Cash Flows from Investing Activities: (71,507,595) (6,667,171) Capital Work in Progress (36,519,616) (27,910,589) Investment in Subsidiaries, Associate & Securities 14,619,000 (102,945,560) Investment in FDR (105,046) 420,221,595 Interest, Dividend & Other Income 9,246,108 11,341,211 Net Cash Received/(Used) in Investing Activities (84,267,148) 294,039,486 C. Cash Flows from Financing Activities: 10,400,400,400 (275,527,154) Cash Equivalent activities: (473,654,483) (275,527,154) Cash Equivalent activities: (473,654,483) (275,527,154) Cash Equivalents at the beginning of the year (42,611,0		September 2016	September 2015	
Cash paid to Suppliers (1,258,476,753) (1,691,960,513) Cash Payment for Operating Expenses (298,789,460) 172,664,798 Cash Generated from Operation 317,467,609 275,085,559 Cash Payment for Income Tax (5,441,739) (23,078,358) Net Cash Generated/(Used) from Operating Activities 312,025,870 252,007,201 B. Cash Flows from Investing Activities:	A. Cash Flows from Operating Activities:			
Cash paid to Suppliers (1,258,476,753) (1,691,960,513) Cash Payment for Operating Expenses (298,789,460) 172,664,798 Cash Generated from Operation 317,467,609 275,085,559 Cash Payment for Income Tax (5,441,739) (23,078,358) Net Cash Generated/(Used) from Operating Activities 312,025,870 252,007,201 B. Cash Flows from Investing Activities:	Cash Received from Customers	1,874,733,822	1,794,381,274	
Cash Payment for Operating Expenses (298,789,460) 172,664,798 Cash Generated from Operation 317,467,609 275,085,559 Cash Payment for Income Tax (5,441,739) (23,078,358) Net Cash Generated/(Used) from Operating Activities 312,025,870 252,007,201 B. Cash Flows from Investing Activities:		(1,258,476,753)	(1,691,960,513)	
Cash Generated from Operation 317,467,609 275,085,559 Cash Payment for Income Tax (5,441,739) (23,078,358) Net Cash Generated/(Used) from Operating Activities 312,025,870 252,007,201 B. Cash Flows from Investing Activities: 312,025,870 252,007,201 B. Cash Flows from Investing Activities: (71,507,595) (6,667,171) Capital Work in Progress (36,519,616) (27,910,589) Investment in Subsidiaries, Associate & Securities 14,619,000 (102,945,560) Investment in FDR (105,046) 420,221,595 Interest, Dividend & Other Income 9,246,108 11,341,211 Net Cash Received/(Used) in Investing Activities (84,267,148) 294,039,486 C. Cash Flows from Financing Activities: (473,654,483) (275,527,154) Short Term Loan Received / (Repaid) (473,654,483) (275,527,154) Short Term Loan Received / (Repaid) (124,939,952) (133,159,250) Dividend paid (1,312,858) (180,029,896) Net Cash Received/(Used) in Financing Activities (301,354,261) (631,327,381) Net Increase / (Decrease) in Cash & Cash Equivalents (73,595,539) (85,280,694) <tr< td=""><td>1 11</td><td>(298,789,460)</td><td>172,664,798</td></tr<>	1 11	(298,789,460)	172,664,798	
Cash Payment for Income Tax (5,441,739) (23,078,358) Net Cash Generated/(Used) from Operating Activities 312,025,870 252,007,201 B. Cash Flows from Investing Activities:		317,467,609	275,085,559	
B. Cash Flows from Investing Activities: Acquisition of Property, Plant & Equipment Capital Work in Progress Investment in Subsidiaries, Associate & Securities Investment in FDR Interest, Dividend & Other Income Net Cash Received/(Used) in Investing Activities: Long Term Loan Received / (Repaid) Short Term Loan Received / (Repaid) Pinancial expenses paid Dividend paid Net Cash Received/(Used) in Financing Activities Net Cash Received/(Used) in Financing Activities Net Cash Received/(Used) in Financing Activities C. Cash Flows from Financing Activities: Long Term Loan Received / (Repaid) Short Term Loan Received / (Repaid) Pinancial expenses paid Dividend paid Net Cash Received/(Used) in Financing Activities Net Increase / (Decrease) in Cash & Cash Equivalents (A+B+C) Cash & Cash Equivalents at the beginning of the year Cash & Cash Equivalents at the end of the year Cash & Cash Equivalents at the end of the year Cash & Cash Equivalents at the order to compute NOCFPS 312,025,870 (71,507,595) (6667,171) (71,507,595) (70,667,171) (71,507,595) (70,667,171) (71,507,595) (70,667,171) (71,507,595) (70,667,171) (71,507,595) (70,667,171) (71,507,595) (70,667,171) (71,507,595) (70,667,171) (71,507,595) (70,667,171) (71,507,595) (70,667,171) (71,507,595) (70,667,171) (70,667,171) (71,507,595) (70,667,171) (70,667,171) (70,667,171) (71,507,595) (70,667,171) (70,667,171) (70,667,171) (71,507,595) (70,667,171) (70,667	-	(5,441,739)	(23,078,358)	
Acquisition of Property, Plant & Equipment Capital Work in Progress Investment in Subsidiaries, Associate & Securities Investment in FDR Interest, Dividend & Other Income Net Cash Received/(Used) in Investing Activities Long Term Loan Received / (Repaid) Short Term Loan Received / (Repaid) Financial expenses paid Dividend paid Net Cash Received/(Used) in Financing Activities Net Cash Received/(Used) in Financing Activities (301,354,261) Net Cash Received/(Used) in Financing Activities (73,595,539) (85,280,694) (84,267,148) (73,595,539) (85,280,694) Number of Shares used to compute NOCFPS	•	312,025,870	252,007,201	
Capital Work in Progress (36,519,616) (27,910,589) Investment in Subsidiaries, Associate & Securities 14,619,000 (102,945,560) Investment in FDR (105,046) 420,221,595 Interest, Dividend & Other Income 9,246,108 11,341,211 Net Cash Received/(Used) in Investing Activities (84,267,148) 294,039,486 C. Cash Flows from Financing Activities: (473,654,483) (275,527,154) Short Term Loan Received / (Repaid) 298,553,032 (42,611,081) Financial expenses paid (124,939,952) (133,159,250) Dividend paid (1,312,858) (180,029,896) Net Cash Received/(Used) in Financing Activities (301,354,261) (631,327,381) Net Increase /(Decrease) in Cash & Cash Equivalents (73,595,539) (85,280,694) (A+B+C) 235,438,025 550,555,534 Cash & Cash Equivalents at the beginning of the year 235,438,025 550,555,534 Cash & Cash Equivalents at the end of the year 161,842,485 465,274,840 Number of Shares used to compute NOCFPS 234,000,000 234,000,000	B. Cash Flows from Investing Activities:			
Capital Work in Progress (36,519,616) (27,910,589) Investment in Subsidiaries, Associate & Securities 14,619,000 (102,945,560) Investment in FDR (105,046) 420,221,595 Interest, Dividend & Other Income 9,246,108 11,341,211 Net Cash Received/(Used) in Investing Activities (84,267,148) 294,039,486 C. Cash Flows from Financing Activities: Used (473,654,483) (275,527,154) Short Term Loan Received / (Repaid) 298,553,032 (42,611,081) Financial expenses paid (124,939,952) (133,159,250) Dividend paid (1,312,858) (180,029,896) Net Cash Received/(Used) in Financing Activities (301,354,261) (631,327,381) Net Increase /(Decrease) in Cash & Cash Equivalents (73,595,539) (85,280,694) (A+B+C) 235,438,025 550,555,534 Cash & Cash Equivalents at the beginning of the year 235,438,025 550,555,534 Cash & Cash Equivalents at the end of the year 161,842,485 465,274,840 Number of Shares used to compute NOCFPS 234,000,000 234,000,000	Acquisition of Property, Plant & Equipment	(71,507,595)	(6,667,171)	
Investment in Subsidiaries, Associate & Securities 14,619,000 (102,945,560) Investment in FDR (105,046) 420,221,595 Interest, Dividend & Other Income 9,246,108 11,341,211 Net Cash Received/(Used) in Investing Activities (84,267,148) 294,039,486 C. Cash Flows from Financing Activities (473,654,483) (275,527,154) (473,654,483) (275,527,154) (473,654,483) (275,527,154) (42,611,081) (124,939,952) (133,159,250) (124,939,952) (133,159,250) (133,159,250) (131,2,858) (180,029,896) (180,	1	(36,519,616)	(27,910,589)	
Interest, Dividend & Other Income Net Cash Received/(Used) in Investing Activities C. Cash Flows from Financing Activities: Long Term Loan Received / (Repaid) Short Term Loan Received / (Repaid) Financial expenses paid Dividend paid Net Cash Received/(Used) in Financing Activities Net Increase / (Decrease) in Cash & Cash Equivalents (A+B+C) Cash & Cash Equivalents at the beginning of the year Cash & Cash Equivalents at the end of the year Number of Shares used to compute NOCFPS 11,341,211 13,41,211 14,241 16,42,485 12,44,000,000 14,341,261 16,341,261 16,341,261 17,341,201 18,42,485 18,4267,148 18,426,110	1	14,619,000	(102,945,560)	
Net Cash Received/(Used) in Investing Activities (84,267,148) 294,039,486 C. Cash Flows from Financing Activities:	Investment in FDR	(105,046)	420,221,595	
C. Cash Flows from Financing Activities: Long Term Loan Received / (Repaid) Short Term Loan Received / (Repaid) Pinancial expenses paid Dividend paid Net Cash Received/(Used) in Financing Activities Net Increase / (Decrease) in Cash & Cash Equivalents (A+B+C) Cash & Cash Equivalents at the beginning of the year Cash & Cash Equivalents at the end of the year Number of Shares used to compute NOCFPS (473,654,483) (275,527,154) (274,843) (124,939,952) (133,159,250) (133,159,250) (133,159,250) (180,029,896) (180,029,	Interest, Dividend & Other Income	9,246,108		
Long Term Loan Received / (Repaid) (473,654,483) (275,527,154) Short Term Loan Received / (Repaid) 298,553,032 (42,611,081) Financial expenses paid (124,939,952) (133,159,250) Dividend paid (1,312,858) (180,029,896) Net Cash Received/(Used) in Financing Activities (301,354,261) (631,327,381) Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C) (73,595,539) (85,280,694) Cash & Cash Equivalents at the beginning of the year 235,438,025 550,555,534 Cash & Cash Equivalents at the end of the year 161,842,485 465,274,840 Number of Shares used to compute NOCFPS 234,000,000 234,000,000	Net Cash Received/(Used) in Investing Activities	(84,267,148)	294,039,486	
Short Term Loan Received / (Repaid) Financial expenses paid Dividend paid Net Cash Received/(Used) in Financing Activities Net Increase / (Decrease) in Cash & Cash Equivalents (A+B+C) Cash & Cash Equivalents at the beginning of the year Cash & Cash Equivalents at the end of the year Number of Shares used to compute NOCFPS 298,553,032 (124,939,952) (133,159,250) (180,029,896) (180,029	C. Cash Flows from Financing Activities:			
Short Term Loan Received / (Repaid) 298,553,032 (42,611,081) Financial expenses paid (124,939,952) (133,159,250) Dividend paid (1,312,858) (180,029,896) Net Cash Received/(Used) in Financing Activities (301,354,261) (631,327,381) Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C) (73,595,539) (85,280,694) Cash & Cash Equivalents at the beginning of the year 235,438,025 (50,555,534) Cash & Cash Equivalents at the end of the year 161,842,485 (465,274,840) Number of Shares used to compute NOCFPS 234,000,000 (234,000,000)	Long Term Loan Received / (Repaid)	(473,654,483)	(275,527,154)	
Financial expenses paid (124,939,952) (133,159,250) Dividend paid (1,312,858) (180,029,896) Net Cash Received/(Used) in Financing Activities (301,354,261) (631,327,381) Net Increase /(Decrease) in Cash & Cash Equivalents (73,595,539) (85,280,694) (A+B+C) 235,438,025 550,555,534 Cash & Cash Equivalents at the beginning of the year 235,438,025 550,555,534 Cash & Cash Equivalents at the end of the year 161,842,485 465,274,840 Number of Shares used to compute NOCFPS 234,000,000 234,000,000	0	298,553,032	(42,611,081)	
Dividend paid (1,312,858) (180,029,896) Net Cash Received/(Used) in Financing Activities (301,354,261) (631,327,381) Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C) (73,595,539) (85,280,694) Cash & Cash Equivalents at the beginning of the year 235,438,025 550,555,534 Cash & Cash Equivalents at the end of the year 161,842,485 465,274,840 Number of Shares used to compute NOCFPS 234,000,000 234,000,000		(124,939,952)	(133,159,250)	
Net Cash Received/(Used) in Financing Activities(301,354,261)(631,327,381)Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C)(73,595,539)(85,280,694)Cash & Cash Equivalents at the beginning of the year235,438,025550,555,534Cash & Cash Equivalents at the end of the year161,842,485465,274,840Number of Shares used to compute NOCFPS234,000,000234,000,000	* *	(1,312,858)	(180,029,896)	
(A+B+C) (53,555,555) (65,255,555) Cash & Cash Equivalents at the beginning of the year 235,438,025 550,555,534 Cash & Cash Equivalents at the end of the year 161,842,485 465,274,840 Number of Shares used to compute NOCFPS 234,000,000 234,000,000		(301,354,261)	(631,327,381)	
Cash & Cash Equivalents at the beginning of the year Cash & Cash Equivalents at the end of the year Number of Shares used to compute NOCFPS 235,438,025 550,555,534 465,274,840 234,000,000 234,000,000		(73,595,539)	(85,280,694)	
Cash & Cash Equivalents at the end of the year 161,842,485 465,274,840 Number of Shares used to compute NOCFPS 234,000,000 234,000,000	· ·	235,438,025	550,555,534	
Number of Shares used to compute NOCFPS 234,000,000 234,000,000		161,842,485	465,274,840	
Operating Cash Flow Per Share 1.33 1.08		234,000,000	234,000,000	
Operating Cases and Cases	Operating Cash Flow Per Share	1.33	1.08	

Sd/-	Sd/-	Sd/-	Sd/-	Sd/-
Chairman	Managing Director	Director	Chief Financial Officer	Company Secretary

Statement of Cash Flows (Unaudited)

For the 1st quarter ended 30 September, 2016

		Amount	: In BDT
		1 July to 30 September 2016	1 July to 30 September 2015
A. Ca	ash Flows from Operating Activities:		
Ca	ash Received from Customers	790,332,920	19,408,110
Ca	ash paid to Suppliers	(320,346,787)	(79,044,259)
Ca	ash Payment for Operating Expenses	(298,789,460)	172,664,798
Ca	ash Generated from Operation	171,196,673	113,028,649
	ash Payment for Income Tax	(5,441,739)	(23,078,358)
	let Cash Generated/(Used) from Operating Activities	165,754,934	89,950,291
B. Ca	ash Flows from Investing Activities:		
A	cquisition of Property, Plant & Equipment	(70,846,915)	(6,312,171)
	Capital Work in Progress	(36,519,616)	(27,910,589)
	nvestment in Subsidiaries, Associate, Securities & Others	14,619,000	(102,945,560)
	nvestment in FDR	(105,046)	420,221,595
In	nterest, Dividend & Other Income	9,246,108	11,341,211
N	let Cash Received/(Used) in Investing Activities	(83,606,468)	294,394,486
C. Ca	Cash Flows from Financing Activities:		
Lo	ong Term Loan Received / (Repaid)	(12,092,441)	(15,168,577)
Sh	hort Term Loan Received / (Repaid)	(20,652,074)	(215,080,865)
Ca	Cash dividend paid	(1,312,858)	(180,029,896)
In	nterest Paid	(36,271,348)	(17,552,659)
N	let Cash Received/(Used) in Financing Activities	(70,328,721)	(427,831,997)
	Net Increase/(Decrease) in Cash & Cash Equivalents A+B+C)	11,819,745	(43,487,220)
Ċ	Cash & Cash Equivalents at the beginning of the year	33,275,154	422,859,123
C	Cash & Cash Equivalents at the end of the year	45,094,899	379,371,903
N	Number of Shares used to compute NOCFPS	234,000,000	234,000,000
	Operating Cash Flow Per Share	0.71	0.38

Orion Pharma Limited

Selected explanatory notes to the financial Statements as at September 30, 2016 (1st Quarter Ended)

Reporting entity

Orion Pharma Limited, earlier called Orion Laboratories Limited was incorporated in 1965 as a private limited company. The Company was converted into a public limited company on July 24, 2010. The registered office of the company is at 153-154, Tejgaon I/A, Dhaka-1208, Bangladesh. The consolidated financial statements of the company comprise the company's and its subsidiaries (together referred to as the "Group" and individually as "Group entities") and the Group's interest in associates and jointly controlled entities.

The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE).

Orion Pharma Limited is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products including vaccines, and health-related consumer products.

Accounting policies and method of computations

This financial statements are consistent with those used in the annual financial statements, prepared and published for the year ended June 30, 2016and there have no changes in accounting policy within the interim reporting period.

Subsequent events

No material events occurred after the reporting date, non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision other than loss of control from subsidiaries of Orion Holdings Limited, Orion Biocare Limited and Orion Natural care Limited.

Disclosure regarding acquisition of fixed assets during the period (PPE) as on 30.09.2016

During the period addition of property plant & equipment is Tk. 13,939,391. Details are hereunder:

SL. NO	Particulars	Addition during the period
1	Land & land development	-
2	Factory & office building	28,560,009
3	Plant & machinery	37,703,958
4	Furniture & fixtures	1,810,998
5	Office equipment	2,758,450
6	Vehicles	13,500
	Total	70,846,915

Sd/-

Sd/ -

Sd/ -

Sd/ -

Sd/-

Chairman

Managing Director

Director

Chief Financial Officer

Company Secretary